Dorzagliatin vs PB-201

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Glucokinase · full Type 2 Diabetes pipeline

Dorzagliatin · Huatangning

Marketed by Hua Medicine under a licence from Roche

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT04531631 · Phase 2 · completed

The study used randomized, triple-blind, placebo-controlled crossover treatment, but enrolled only 18 participants and measured a mechanistic insulin-response biomarker rather than a clinical diabetes outcome. Because the registry provides no primary-endpoint results, it is not possible to determine whether the comparison met its prespecified endpoint.

Reported efficacy

first phase insulin response to glucose (10 mins): Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). (missed)

Result source: NCT04531631

PB-201

Developed by PegBio and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT05102149 · Phase 3 · status unknown

This is a randomized, fully blinded trial with both an active and a placebo comparator, testing a recognized clinical measure (HbA1c) in a reasonably large group of patients, but no results are available yet to confirm whether PB-201 met its goal.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDorzagliatinPB-201
HbA1c, change—Not posted · NCT03173391—Not reported
Body weight, change (kg)—Not posted · NCT03173391—Not reported
HbA1c below 7%—Not posted · NCT03173391—Not reported
Fasting plasma glucose, change—Not posted · NCT03173391—Not reported
3-point MACE (% with event)—Not posted · NCT03173391—Not reported

HbA1c, change

Dorzagliatin
—Not posted · NCT03173391
PB-201
—Not reported

Body weight, change (kg)

Dorzagliatin
—Not posted · NCT03173391
PB-201
—Not reported

HbA1c below 7%

Dorzagliatin
—Not posted · NCT03173391
PB-201
—Not reported

Fasting plasma glucose, change

Dorzagliatin
—Not posted · NCT03173391
PB-201
—Not reported

3-point MACE (% with event)

Dorzagliatin
—Not posted · NCT03173391
PB-201
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

PB-201: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Dorzagliatin
Acute (first-phase) insulin response to glucose, AIRg, dorzagliatin vs placebo. GCK-MODY group (n=8): 226.1 ± 64.3 vs 179.4 ± 117.7 pmol/L, P = 0.164. Type 2 diabetes group (n=10): -2.3 ± 22.6 vs 31.5 ± 22.1 pmol/L, P = 0.006 (dorzagliatin lower than placebo). NCT04531631 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dorzagliatin's landscape · PB-201's landscape